NCT07119918View on ClinicalTrials.gov

PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

5,276

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2029

Conditions
Symptomatic Intracranial Atherosclerotic Stenosis
Interventions
DRUG

Recaticimab

Recaticimab 300mg subcutaneous Q8W for 1 year.

DRUG

Placebo

Matched placebo subcutaneous Q8W for 1 year.

Trial Locations (1)

510120

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER